CUMYL-3TMS-PRINACA
Synthetic cannabinoid
| CUMYL-3TMS-PRINACA | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 1400742-16-6 |
| PubChem | 119025276 |
| DrugBank | |
| ChemSpider | 52085456 |
| KEGG | |
CUMYL-3TMS-PRINACA is a synthetic cannabinoid that has been used in scientific research and is known for its potent activity at the cannabinoid receptors. It is a member of the indazole-3-carboxamide family of synthetic cannabinoids, which are often used as active ingredients in designer drugs.
Chemical Structure[edit | edit source]
CUMYL-3TMS-PRINACA is chemically classified as an indazole-3-carboxamide. Its IUPAC name is 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide. The compound features a cyanobutyl group attached to the indazole core, which is a common structural motif in many synthetic cannabinoids.
Pharmacology[edit | edit source]
CUMYL-3TMS-PRINACA acts as a potent agonist at the CB1 and CB2 cannabinoid receptors. These receptors are part of the endocannabinoid system, which plays a role in regulating various physiological processes including mood, appetite, and pain sensation. The high affinity of CUMYL-3TMS-PRINACA for these receptors contributes to its psychoactive effects.
Legal Status[edit | edit source]
The legal status of CUMYL-3TMS-PRINACA varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of accepted medical use. It is often included in legislation targeting synthetic cannabinoids and other novel psychoactive substances.
Health Effects[edit | edit source]
The use of CUMYL-3TMS-PRINACA, like other synthetic cannabinoids, can lead to a range of adverse health effects. These may include tachycardia, hypertension, nausea, vomiting, anxiety, and hallucinations. Severe cases can result in seizures, renal failure, and death.
Synthesis[edit | edit source]
The synthesis of CUMYL-3TMS-PRINACA involves the reaction of an indazole-3-carboxylic acid derivative with a suitable amine. The process typically requires careful control of reaction conditions to ensure the desired product is obtained with high purity.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
